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neurodegenerative disorder caused by a CAG triplet expansion
in exon 10 of the ATXN3 gene. The resultant expanded poly-
glutamine stretch in the mutant ataxin-3 protein causes a
gain of toxic function, which eventually leads to neurodegener-
ation. One important function of ataxin-3 is its involvement in
the proteasomal protein degradation pathway, and long-term
downregulation of the protein may therefore not be desirable.
In the current study, we made use of antisense oligonucleotides
to mask predicted exonic splicing signals, resulting in exon 10
skipping from ATXN3 pre-mRNA. This led to formation of a
truncated ataxin-3 protein lacking the toxic polyglutamine
expansion, but retaining its ubiquitin binding and cleavage
function. Repeated intracerebroventricular injections of the
antisense oligonucleotides in a SCA3 mouse model led to
exon skipping and formation of the modified ataxin-3 protein
throughout the mouse brain. Exon skipping was long
lasting, with the modified protein being detectable for at least
2.5 months after antisense oligonucleotide injection. A reduc-
tion in insoluble ataxin-3 and nuclear accumulation was
observed following antisense oligonucleotide treatment, indi-
cating a beneficial effect on pathogenicity. Together, these
data suggest that exon 10 skipping is a promising therapeutic
approach for SCA3.Received 2 February 2017; accepted 24 June 2017;
http://dx.doi.org/10.1016/j.omtn.2017.06.019.
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Spinocerebellar ataxia type 3 (SCA3) is a hereditary neurodegener-
ative disorder characterized by ataxia, usually presenting in the
third to sixth decade of life.1 Pathoanatomical studies of SCA3
patient brains have shown neurodegeneration in the cerebellum,
thalamus, midbrain, pons, medulla, and spinal cord.2 SCA3 is one
of nine known polyglutamine (polyQ) disorders. The causative
mutation for polyQ disorders is a CAG codon repeat expansion
in the coding region of a gene, which upon translation leads to
an expanded glutamine amino acid stretch in the causative protein.
It is thought that the polyQ expansion leads to a gain of toxic pro-
tein function.3 In the case of SCA3, the CAG repeat expansion is
located in exon 10 of the ATXN3 gene, encoding the ataxin-3 pro-
tein.4 In the normal population, an ATXN3 CAG repeat length of 10
to 51 repeats is observed, while SCA3 patients have repeat lengths of
55 or longer.5232 Molecular Therapy: Nucleic Acids Vol. 8 September 2017 ª 2017 T
This is an open access article under the CC BY license (http://creatiAtaxin-3 is a ubiquitously expressed deubiquitinating enzyme of
around 42 kDa, with its main function in the proteasomal
protein degradation pathway.6 Several ataxin-3 isoforms have
been described,7 with the predominant ataxin-3 isoform (NCBI:
NM_004993) in human and mouse brain containing three ubiqui-
tin-interaction motifs (UIMs).8,9 It has been shown that the interac-
tion between ataxin-3 and K48-linked poly-ubiquitin chains is depen-
dent on the first two UIMs, while the third UIM located C-terminally
of the polyQ stretch appears dispensable for this process.10,11 Upon
binding of poly-ubiquitin chains by the UIMs, the N-terminal cata-
lytic Josephin domain of ataxin-3 can cleave these chains. Through
this process, ataxin-3 can facilitate substrate entry into the protea-
some, as well as mediate other ubiquitin-dependent pathways.11,12
Given the monogenetic nature, SCA3 is an ideal candidate for thera-
pies that specifically target the ATXN3 gene product. Indeed, several
RNAi strategies that downregulate ataxin-3 protein expression have
been investigated over the last decade. Non-allele-specific silencing
of ataxin-3 was found to reduce neuropathology in a SCA3 rat
model.13 Additionally, by making use of a SNP associated with the
mutant ATXN3 allele (rs12895357), an allele-specific RNAi-mediated
reduction of mutant ataxin-3 decreased neuropathological abnormal-
ities and/or motor deficits in both SCA3 rats and mice.14–16 Antisense
oligonucleotides (AONs) are another tool under investigation for
therapeutic intervention in SCA3. Particularly for use in the brain,
AONs offer several favorable properties, including good distribution
throughout the brain after infusion in the cerebrospinal fluid, excel-
lent uptake by neurons and other brain cells, high stability with a
half-life of several months, and a promising tolerability in clinical tri-
als thus far.17 Another advantage of using AONs is that they can also
be used to redirect splicing by including or excluding specific exons.
Here, we describe an AON-based strategy to redirect splicing of the
ataxin-3 pre-mRNA. The aim of this approach is to remove the toxiche Author(s).
vecommons.org/licenses/by/4.0/).
Figure 1. Antisense Oligonucleotide-Mediated Removal of the Polyglutamine Repeat from the Ataxin-3 Protein
(A) Schematic representation of the experimental approach to remove exon 10 from the ataxin-3 mRNA approach based on transcript ENST00000558190 (361 amino acids)
using antisense oligonucleotides (AONs) targeting predicted splicing motifs within exon 10. Skipping of exon 10 leads to a novel stop codon at the start of exon 11. The
resulting ataxin-3 protein contains 291 amino acids and lacks the polyQ repeat and C terminus (depicted as transparent region). Five different AONs against exon 10 were
tested for functionality by transfection in SCA3 patient-derived fibroblasts. (B and C) An internally truncated ataxin-3 RNA lacking the CAG repeat (D exon 10) (B) and a
truncated ataxin-3 protein lacking the polyQ-containing C terminus (D C terminus) (C) were detected. Nt = nucleotides.
www.moleculartherapy.orgpolyQ repeat from the mutant ataxin-3 protein, thereby removing the
cause of SCA3. Using an AON targeting exon 10 of ATXN3, this exon
is removed from the pre-mRNA, resulting in a truncated ataxin-3
protein consisting of 291 amino acids with a predicted mass of
34 kDa. Functional testing of the truncated protein lacking the polyQ
domain and the third UIM showed that this modified ataxin-3 can
still bind ubiquitin chains similar to wild-type ataxin-3. Finally, the
AON was tested in the MJD84.2 SCA3 mouse model using repeated
bolus injection in the lateral ventricle of the brain. Remarkably, this
led to widespread distribution of the AON with ataxin-3 protein
modification observed throughout the brain.
RESULTS
Exon 10 Skip Leads to a Truncated Ataxin-3 Protein Lacking the
PolyQ Repeat
Removal of exon 10 from the ataxin-3 pre-mRNA results in a stop
codon right at the start of exon 11. As a consequence, the resulting
ataxin-3 protein is truncated to amino acid 291 (Figure 1A) and lacks
the C-terminal region that contains the toxic polyQ repeat, as well as
UIM3. A total offive splicemodulatingAONswere designed targeting
exon 10 (Table 1) and were transfected in SCA3 patient-derived fibro-
blasts. RT-PCR and western blot analysis showed that three of the
tested AONs induced exon 10 skipping as both expression of a shorter
ataxin-3 transcript (D exon 10) and truncated protein (D C terminus)were observed (Figures 1B and 1C). Although AON 10.4 contained an
SNP (rs12895357) associated with the expanded allele,18,19 we always
observed modification of both wild-type and mutant alleles.
Ataxin-3 Lacking PolyQ Binds and Cleaves Ubiquitin Chains
Similar to Wild-Type
Due to the novel stop codon in exon 11 induced by exon 10 skipping,
the ataxin-3 D C terminus protein lacks the third UIM (Figure 1A).
To determine whether ataxin-3 D C terminus was still capable
of binding ubiquitin chains, we made use of a U2OS 2-6-3 cell line
containing a large array of LacO repeats,20 in which expression of
mCherry-LacR-RNF8 fusion protein leads to localized ubiquitilation
of the chromatin.21 Ataxin-3 subsequently binds the ubiquitins
as mediated by the UIMs, resulting in colocalization between
mCherry-RNF8 and GFP-ataxin-3. We have previously shown this
colocalization of ataxin-3 to the LacO array as a reliable marker for
ubiquitin binding activity of ataxin-3.22 Here, we tested several
GFP-tagged ataxin-3 proteins for ubiquitin binding capacity (Fig-
ure 2A). In line with previous observations, the ataxin-3 with either
10Q or 71Q can readily bind ubiquitin chains and hence colocalized
with the ubiquitin moieties at the array (Figures 2B and 2C). Ataxin-3
with all three UIMs inactivated by point mutations (L229A, L249A,
and L340A), termed UIMs L > A, colocalized with the ubiquitin con-
jugates to a significantly lower extent, confirming the specificity of theMolecular Therapy: Nucleic Acids Vol. 8 September 2017 233
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Molecular Therapy: Nucleic Acidsassay. Ataxin-3 D C terminus colocalized with the ubiquitin conju-
gates at the array to a similar extent as wild-type ataxin-3, indicating
that the ubiquitin chain binding capacity of the protein was retained
despite lacking the third UIM.
To confirm the ubiquitin cleavage capacity of ataxin-3 D C terminus,
purified HIS-ataxin-3 proteins (Figure 2D) were incubated with
K63-linked hexa-ubiquitin chains. Similar to ataxin-3 10Q and
71Q, ataxin-3D C terminus was able to cleave ubiquitin chains as evi-
denced by the appearance of shorter ubiquitin fragments (penta- and
tetra-ubiquitin) (Figure 2E). In line with previous reports, deletion
of a cysteine in the Josephin domain (DC14) abolished ataxin-3 ubiq-
uitin protease activity.23 Together, these results indicate that removal
of the C terminus from ataxin-3 does not interfere with ubiquitin
binding and cleavage capacity.
Ataxin-3 Exon Skipping in Mouse Brain
To determine whether the ataxin-3 exon skip strategy is feasible
in vivo, the four AONs against ATXN3 RNA were tested in the
MJD84.2 mouse model.24 The MJD84.2 mouse contains the full
human ATXN3 gene with 84 CAGs including introns and flanking
regions, making it a suitable SCA3 rodent model to assess human
ATXN3 splicing events in vivo. Sequencing analysis showed that
the human ATXN3 gene in this mouse also contains the SNP
(rs12895357) and thus has full complementarity with AON 10.4
(data not shown). To assess AON efficacy, the AONs targeting
exon 10 were injected as a single 500 mg intracerebroventricular
(ICV) bolus in anesthetized hemizygous MJD84.2 mice. At 2 weeks
after the injection, exon skipping was analyzed in the cortex and cer-
ebellum (Figure 3A). AON efficacy in both brain regions was similar
to that observed in SCA3 fibroblasts transfections, with AON 10.4
being most efficient. Sanger sequencing confirmed that the shorter
ATXN3 RNA was the result of exon 10 skipping in the human tran-
script. In line with the transcript modification, a modified D C termi-
nus ataxin-3 protein of approximately 36 kDa in size was observed in
the treated animals (Figure 3B). Protein modification appeared more
efficient in the cortex than cerebellum. In the untreated animals, an
ataxin-3 protein of similar size asDC terminus ataxin-3 was observed
as well, perhaps indicating the truncated ataxin-3 protein is a natu-
rally occurring isoform or cleavage fragment in these mice.
AON Effect Lasts at Least 2.5 Months in Mouse Brain
Despite relatively high expression of mutant ataxin-3 throughout the
brain, hemizygous MJD84.2 mice do not develop an ataxic phenotype234 Molecular Therapy: Nucleic Acids Vol. 8 September 2017on beamwalk tests,25 but do develop a neuronal phenotype consisting
of nuclear localization of mutant human ataxin-3 in certain neuronal
populations from around 2 months of age.25,26 To assess long-term
efficacy of AONs in the mouse brain and the effect on the neuronal
phenotype, a total of 27 mice were treated with either PBS, scrambled
control AON or AON 10.4, and sacrificed 2.5 months after the last
injection. With repeated injections, a total ICV dose of 1 mg AON
was achieved over a 3 week period (Figure 4A). There was a clear
dose-dependent effect on protein modification, with a 500 mg dose
resulting in 17% protein modification in the cortex and 1 mg AON
resulting in 37% protein modification (Figure S1). At the time of sac-
rifice, ATXN3 exon 10 skipping was seen at RNA level in all tested
brain regions (Figures 4B and S2A), 40% ataxin-3 modification was
seen in protein lysates from the brainstem and cortex, while 20%
ataxin-3 modification was seen in the cerebellum (Figures 4C, 4D,
and S2B). This indicates that the AONs have distributed throughout
the brain and are stable and effective for at least 2.5 months post in-
jection. No deleterious effect of the AON on bodyweight or motor
behavior (Figure S3) was observed during the course of the study.
AON Treatment Reduces Insoluble Ataxin-3 and Prevents
Nuclear Accumulation
Protein aggregation is considered a hallmark of polyQ disorders. It has
been implicated as a pathogenic mechanism for these diseases,27,28 and
mutant ataxin-3 aggregates are found in the brain of SCA3 patients.29
Using protein lysates from three different brain regions, we performed
filter trap assays30 to detect the level of insoluble ataxin-3 proteins (Fig-
ure 4F). Insoluble ataxin-3 protein was detected in the transgenic
MJD84.2 mice expressing mutant ataxin-3, but not in wild-type mice.
The highest level of insoluble ataxin-3 was detected in the cerebellum.
No significant difference in ataxin-3 insolubility was observed between
scrambledAON- and PBS-treated SCA3 animals. Following AON 10.4
treatment, there was significantly less insoluble ataxin-3 detected
compared to animals treated with scrambled AONor PBS (Figure 4G).
To further assess the effect of AON treatment on expanded ataxin-3
pathogenicity, we performed immunofluorescent examination of
SCA3 mouse brains in mice that were 5.5 months of age at time of
sacrifice. We observed strong nuclear ataxin-3 staining throughout
the brainstem, but specifically in the substantia nigra.Nuclear accumu-
lation of expanded ataxin-3 has been shown to aggravate neurodegen-
eration and formation of aggregates in vivo31 and is therefore a useful
marker to assess ataxin-3 toxicity. In fact, nuclear localization of
ataxin-3 appears to be required to induce symptoms of SCA3.31 In
the MJD84.2 mouse model, we observed strong nuclear localization
of ataxin-3 in the substantia nigra. Therefore, we used tyrosine hydrox-
ylase staining to delineate the substantia nigra in sagittal brain sections
(Figure 5A). The intensity of ataxin-3 nuclear localization in the sub-
stantia nigra was markedly reduced in mice treated with 10.4 AON
when compared to animals treated with control AON (Figure 5B).
DISCUSSION
In this work, we describe an AON-mediated exon skipping strategy
for SCA3. Our therapeutic approach removes the polyQ repeat
Figure 2. Ataxin-3 D C Terminus Is Capable of
Binding and Cleaving Ubiquitin Chains
(A) Schematic representation of mCherry and GFP fusion
proteins with their functional domains. The ubiquitin ligase
RNF8 was fused to mCherry and LacR. Atatxin-3 was
fused to GFP. Ubiquitin-interacting motifs (UIMs) of
ataxin-3 are depicted in blue. Inactivating substitution
mutations are indicated by red crosses. (B) Tethering of
the mCherry-LacR-RNF8 fusion protein to a LacO array in
the chromatin in U2OS 2-6-3 cells (red signal) results
in local chromatin ubiquitylation at the LacO array.21
GFP-ataxin-3 proteins bind the RNF8-induced ubiquitin
moieties at the LacO array, thereby colocalizing with
mCherry-LacR-RNF8 (green).22 Representative images
are shown in the panel. The arrows indicate the chromatin
localized RNF8 and ataxin-3 where GFP intensity was
quantified. (C) Quantification of increase in GFP-tagged
ataxin-3 signal at the array after coexpression with
mCherry-LacR-RNF8. The values represent the mean +
SEM of >40 cells examined from two independent ex-
periments. (D) Schematic representation of HIS-tagged
ataxin-3 proteins used in ubiquitin cleavage reaction. The
C14 deletion (DC14) is known to inactivate catalytic ac-
tivity. (E) Purified HIS-ataxin-3 proteins were incubated for
16 hr with K63-linked hexa-ubiquitin to determine ubiq-
uitin cleavage activity.
www.moleculartherapy.orgfrom the protein and therefore removes the cause of SCA3. This
approach is superior to current treatments that only treat symptoms
and not the cause of disease. It may also have some specific advantages
over strategies that aim to lower expression of the ataxin-3 protein,
since ataxin-3 has important cellular functions32 in regulating pro-
tein degradation,23 transcription,33 and DNA damage response.34
Though ataxin-3 knockout appears tolerated in mice without major
deficits,35–37 it is currently unknown whether long-term downregula-
tion will be tolerated in patients. Therefore, it is more prudent to
avoid complete ataxin-3 downregulation. We provide evidence that
repeated ICV injections of AONs in a transgenic SCA3 mouse model
leads to substantial ataxin-3 RNA and protein modification (ataxin-3
D C terminus) throughout the mouse brain and is able to alleviate
ataxin-3 nuclear accumulation and insolubility.Molecular TheraAtaxin-3 D C terminus still contains the main
known functional domains, namely, the cata-
lytic Josephin domain (amino acids 1–180)
and the valosin-containing protein (VCP)-in-
teracting motif (amino acids 257–291).38 The
Josephin domain is required for ataxin-3 deubi-
quitinating activity,39 in conjunction with UIM
1 and 2 coordinating specific ubiquitin chain
cleavage.11,12 The UIMs are required for the
ubiquin binding capacity of ataxin-3, but the
third UIM is not considered essential for this
process.10,11,40,41 The current study confirms
this by showing the wild-type ubiquitin binding
capacity of D C terminus ataxin-3 in a cellularcontext (Figures 2B and 2C). Previous experiments have shown
that removing the C terminus from ataxin-3 does not impair its deu-
biquitinating activity.42 Our results are in line with these previous
studies and show that ataxin-3 D C terminus is capable of cleaving
ubiquitin chains (Figure 2E).
Ataxin-3 interaction with VCP is thought to be crucial for the activa-
tion of ataxin-3 and regulating the endoplasmic reticulum-associated
degradation pathway through protein extraction from the endo-
plasmic reticulum.43,44 Ataxin-3 D C terminus still contains the
VCP binding motif.38 Retainment of the VCP binding site in
ataxin-3 D C terminus may be of particular importance, as a mouse
model expressing only the ataxin-3 N terminus up to amino acid
259 resulted in extranuclear neuronal aggregates and premature deathpy: Nucleic Acids Vol. 8 September 2017 235
Figure 3. AON Screening In Vivo
500 mg AONs were injected intracerebroventricularly in MJD84.2 mice. After 2 weeks, mice were sacrificed and RNA and protein were isolated from the cortex and
cerebellum. (A) RT-PCR using primers flanking ATXN3 exon 10 shows the full-length human ataxin-3 PCR product with 84 CAG repeats, the mouse ataxin-3 with six CAG
repeats, as well as the shorter ataxin-3 lacking exon 10 after injection of AON 10.1 and 10.4 (D exon 10). Sanger sequencing trace of D exon 10 RNA is shown below with
corresponding reading frame. (B) Western blotting shows the full-length human ataxin-3 protein with 84 Q repeats, the mouse ataxin-3 protein with 6 Qs, and the truncated
ataxin-3 protein lacking the C terminus. Of the four AONs tested, AON 10.1 and 10.4 show the most efficient modification of the human ataxin-3 protein (D C terminus).
Ctx = cortex, cb = cerebellum.
Molecular Therapy: Nucleic Acidsat 12 months of age.45 This phenotype was associated with distur-
bances of endoplasmic reticulum-mediated unfolded protein
response, possibly indicating the importance of ataxin-3 and VCP
interaction in maintaining endoplasmic reticulum homeostasis.
A recent study by Liu and colleagues46 testing several different oligo-
nucleotide chemistries found that ATXN3 exon 10 could be skipped
with CAG-targeting oligonucleotides, and the ataxin-3 D C terminus
protein was also observed in these experiments. Both mutant and
wild-type ataxin-3 alleles will be targeted by the AON, as the AON
is complementary to the canonical exon 10 sequence. Indeed, we
observed a similar level of exon skipping for the mutant and wild-
type allele in SCA3 patient-derived fibroblasts (Figures 1B and 1C).
This observation underlines the importance of determining the pro-
tein function of ataxin-3 D C terminus in a neuronal context, as the
proposed AON treatment may lead to high protein modification
levels throughout the brain.
Apart from retaining wild-type ataxin-3 function, an important
concern is that the ataxin-3 D C terminus protein should not result
in a gain of toxic function. An ataxin-3 protein variant corresponding
exactly to the D C terminus protein resulting from exon 10 skipping
has been tested in a yeast model and rat cerebellar granule cells, where
it was shown that this protein indeed did not aggregate, but in some
tests showed a mild increase in toxicity compared to the wild-type
ataxin-3 protein.47,48 Whether these results can be extrapolated to
the in vivo situation will have to be determined, but we did not
observe overt signs of toxicity in the AON 10.4-treated mice express-
ing ataxin-3 D C terminus based on bodyweight and locomotor activ-
ity (Figures S3A and S3B). Additionally, no increase in cell death was
observed in fibroblasts treated with AON 10.4 (Figure 1C), or U2OS
cells transfected with GFP-ataxin-3 D C terminus (Figure 2B), indi-
cating that ataxin-3 D C terminus is not toxic to these cells. Interest-
ingly, a study investigating the transcript diversity of ataxin-3 in hu-
mans found two naturally occurring ataxin-3 isoforms generated by a
stop codon after exon 9. Indeed, we observed an ataxin-3 protein of
similar size to our D C terminus protein in untreated SCA3 animals236 Molecular Therapy: Nucleic Acids Vol. 8 September 2017(Figure 3B), perhaps indicating that this protein is also expressed in
the transgenic mouse brain. If ataxin-3D C terminus is indeed a natu-
rally occurring isoform, this may suggest that the protein is likely not
a toxic variant. To more comprehensively test whether ataxin-3 D C
terminus is fully functional and not toxic to cells, it will be useful to
express ataxin-3 D C terminus in ataxin-3 knockout mice in future
studies.
The current study used the MJD84.2 mouse model.24 This mouse
model contains the full human ATXN3 gene, including flanking re-
gions and introns, which is essential when testing splice modulating
AONs. Indeed, similar potency of the exon 10-targeting AONs was
found when comparing patient-derived fibroblast results with the
in vivo ICV injections. Repeated bolus injections of AON 10.4 were
tolerated and led to increased levels of ataxin-3 protein modification.
No significant reduction in the level of soluble mutant ataxin-3 with
western blot analysis was observed (Figure 4C), however, a reduction
in the amount of insoluble ataxin-3 was observed in the filter trap
assay (Figure 4F).
We did not consistently observe strong nuclear accumulation of
ataxin-3 in the deep cerebellar nuclei as previously reported in the
MJD84.2 mice.26 Though we were not able to detect clear aggregates
in any brain regions, ataxin-3 nuclear localization was readily seen in
the substantia nigra, in line with previous reports.49 The molecular
SCA3 phenotype of the mice was beneficially effected by AON treat-
ment, with a reduction of insoluble ataxin-3 species observed in filter
trap assays, and less nuclear ataxin-3 accumulation in the substantia
nigra. The AONs were functionally active for at least 2.5 months, in
line with previous studies using similar AON chemistries in spinal
muscular atrophy mice reporting effects lasting for over 6 months
after ICV injection.50
Clinical application of AONs currently seems promising. In clinical
trials, intrathecal injection of 20-O-methoxy-ethyl (MOE)-modified
AONs in children with spinal muscular atrophy have shown AON
half-lives in the cerebrospinal fluid (CSF) of 4–6 months, with good
Figure 4. In Vivo Assessment of AON-Mediated Removal of the Ataxin-3 Polyglutamine Repeat in MJD84.2 Mice
(A) Schematic representation of experimental design. At 2.5 months of age (time point 0), mice were cannulated and 500 mg of AON 10.4 was injected ICV. Additional
250 mg injections were performed at week 3 and 4 resulting in a total dose of 1 mg. Mice were sacrificed after 3.5 months. n = 6 per group. (B) RT-PCR specific for human
ATXN3 with primers flanking exon 10 shows full-length mutant ataxin-3 and ataxin-3 lacking exon 10 (D exon 10) in treated mice. (C) Modified ataxin-3 protein was seen for
AON-treated transgenic mice in all tested brain regions: the brainstem and cortex are shown. Each lane represents one mouse. (D) Quantification of band intensity from (C)
shows up to 40% ataxin-3 modification. Reported is modified ataxin-3 percentage of the sum of mutant and modified ataxin-3 band intensities. (E) Staining with an antibody
against the phosphorothioate backbone shows that AONs are located throughout the entire mouse brain following ICV infusion. The upper panel shows a mouse sacrificed
3 months after injection with AON 10.4, and the lower panel depicts a PBS injected mouse. Higher magnification of the cerebellum shows good AON uptake in the Purkinje
cells. (F) Filter retardation assay indicates that mice carrying the transgene show insoluble ataxin-3 in all tested brain regions when stained with 1H9 anti-ataxin-3 antibody.
A reduction in insoluble ataxin-3 is seen in AON 10.4-treated animals compared to PBS- and control AON-treated animals. (G) Quantification of dot intensity from (F) reveals
significant reduction in filter trapped insoluble ataxin-3 protein in AON 10.4-treated mice. *p < 0.05 and **p < 0.01.
www.moleculartherapy.orgtolerability and improvement in patients motor function.51 This sug-
gests that relatively infrequent dosing, such as intrathecal AON injec-
tions every 6 months, could be a feasible treatment regimen for SCA3.
The removal of the polyQ repeat from ataxin-3 is likely to delay dis-
ease progression and restrict brain damage. In case of high efficacy of
the treatment, it could even stop disease progression completely.
Since the mouse model used here does not present with ataxic symp-
toms, we were unable to assess an effect of our AON treatment on
reversal of the motor phenotype. However, studies in mice whereexpression of mutant ataxin-3 was halted during the early stage
of the disease have shown that a reversal of the motor symptoms
was possible.52 A similar observation has been made when polyQ
expanded Huntingtin protein was downregulated using AONs in a
Huntington’s disease mouse model.53 This is a promising observa-
tion, but whether the same could be possible in humans is currently
unknown. Because of the autosomal dominant nature of SCA3, pa-
tients can start therapy before onset of clinical symptoms, improving
likelihood of a beneficial effect.Molecular Therapy: Nucleic Acids Vol. 8 September 2017 237
Figure 5. AON Treatment Reduces Nuclear Ataxin-3 Accumulation in Substantia Nigra of SCA3 Mice
(A) The nuclear accumulation of ataxin-3 was determined by staining with the 1H9 monoclonal antibody. Only cells of the substantia nigra expressing tyrosine hydroxylase
were used in this analysis, as these showed the most intense nuclear ataxin-3 signal. (B) Quantification of staining intensity revealed that transgenic mice treated with 10.4
AON showed a decrease in nuclear ataxin-3 accumulation, likely due to the reduction in full-length mutant ataxin-3 levels. Analysis performed on four control AON versus
three 10.4 AON-treated mice and four sections per mouse is shown. Mean + SEM, evaluated with Student’s t test, **p < 0.01.
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AON Design and Synthesis
Oligonucleotides targeting exon 10 (Table 1) of the human ATXN3
transcript NCBI: NM_004993 were designed according to previously
described guidelines.54,55 AONs targeted predicted exonic splicing
enhancer sites according to the Human Splicing Finder.56 Specificity
of the AONs was checked using BLAST analysis. The synthesis and
purification of the oligonucleotides were performed as described pre-
viously.57 AONs were fully modified with 20-O-methoxyethylribose
nucleotides and a phosphorothioate backbone. Cytosine residues
were methylated to reduce immunostimulatory effects of the oligonu-
cleotides in vivo.58
Cell Culture
SCA3 fibroblast (GM06153) cell lines were obtained from Coriell Cell
Repositories (Camden) and maintained in minimal essential medium
(MEM) (Gibco and Invitrogen), containing 15% fetal bovine serum
(FBS) (Clontech), 1% Glutamax (Gibco), and 100 U/mL penicillin/
streptomycin (Gibco).
Human U2OS 2-6-3 cells containing 200 copies of a LacO (256)/
TetO (96)-containing cassette of 4 Mbp20 were cultured in
DMEM (Gibco), supplemented with 10% FBS, 1% glutamax, and
100 U/mL penicillin/streptomycin. All cells were grown at 37C
and 5% CO2.
Transfections
Transfections of AONs were performed as described previously.40
Briefly, fibroblasts were replated the day before transfection. AONs
were diluted to 200 nM in MEM without supplements containing
0.3% lipofectamine (Life Technologies). The cells were incubated
with the transfection mixture for 4 hr, after which a three times vol-238 Molecular Therapy: Nucleic Acids Vol. 8 September 2017ume of normal growthmediumwas added. Cells were harvested 1 day
after transfection for RNA analysis or 2 days after transfection for
protein analysis.
Plasmid transfections were performed similar to AON transfections
using 1 to 1.5 mg of plasmid DNA (per 9.6 cm2 well) in 0.6 mL
MEM with 0.6% lipofectamine. Cells were imaged for GFP or
mCherry protein expression the next day using a Leica DM-5500B
fluorescent microscope (Leica Microsystems) at 63 magnification
as previously described.22
Mice and Oligonucleotide Injections
MJD84.2 SCA3mice24 were obtained from Jackson laboratories, stock
number 012705. All animal experiments were carried out in accor-
dance with European Communities Council Directive 2010/63/EU
and were approved by the Leiden University Animal Ethical Com-
mittee. Animals were housed singly after surgery in individually
ventilated cages with a 12 hr light/dark cycle. Food and water were
available ad libitum. Mice were bred with wild-type C57/BL6 mice
to obtain wild-type or hemizygous SCA3 animals. Mice were
genotyped using ear clip tissue material and a Phire Animal Tissue
Direct PCR Kit (Thermo Fisher Scientific), using forward primer
hAtxn3int10fw1 and reverse primer hAtxn3int10rev1 (see Table 2)
targeting the human ATXN3 transcript and mAtxn3int10fw1 and
mAtxn3int10rev1 primers targeting mouse ataxin-3 as positive con-
trol for DNA isolation. Multiplex PCR was performed following man-
ufacturer’s instructions with an annealing temperature step of 61.5C,
20 s of extension at 72C, and a total of 35 PCR cycles.
For AON injections, a total of 34 male mice aged 2 to 2.5 months and
weighing approximately 25 g were anesthetized using 1.5% isoflurane
gas anesthesia and mounted on a Kopf stereotactic device (Kopf
Table 2. Primer Sequences
Target Gene Primer Name Application Sequence (50 to 30)
ATXN3 hATXN3_FL_rev2 cDNA synthesis TCCTACAACCGACGCATTGT
ATXN3 hATXN3_FL_Fw1 cloning ATGGAGTCCATCTTCCACGA
ATXN3 hATXN3_FL_Rev cloning CGCATTGTTCCACTTTCCCA
ATXN3 hATXN3ex4Fw1 RT-PCR GCCTTGAAAGTTTGGGGTTT
ATXN3 hATXN3ex11Rev1 RT-PCR ACAGCTGCCTGAAGCATGTC
ATXN3 MJD_gen_fw1 genotyping PCR ATACTTCACTTTTGAATGTTTCAGAC
ATXN3 MJD_gen_rev1 genotyping PCR GAATGGTGAGCAGGCCTTAC
mATXN3 mAtxn3int10fw1 genotyping PCR GCGTTGTTTTAACAGATATTCACG
mATXN3 mAtxn3int10rev1 genotyping PCR TGTGAATGGACAGAAAGCAAA
ATNX3 hATXN3_DC14_fw mutagenesis GAAACAAGAAGGCTCACTTGCTCAACATTGCCTGAA
ATXN3 hATXN3_DC14_rev mutagenesis TTCAGGCAATGTTGAGCAAGTGAGCCTTCTTGTTTC
www.moleculartherapy.orgInstruments). Cannulas of 26 gauge and 3 mm in length (Plastics
One) were implanted in the right lateral ventricle, according to the
following coordinates: 0.2mm posterior and 1.0mm lateral to bregma
and was lowered to a depth of 2.2 mm from the skull surface. The can-
nulas were subsequently fixed to the skull surface using dental cement
and closed with a screw-on internal dummy cannula. AONs for
in vivo injections were dissolved in sterile PBS without calcium or
magnesium to a concentration of 50 mg/mL, as determined by UV
spectrometry, and filtered using a 0.22 mm spin column filter.
AONs or PBS were injected ICV through a 28 gauge needle placed
in the guide cannula at a rate of 1 mL/min using a Hamilton syringe
mounted in a syringe infusion pump (Stoelting). The first AON injec-
tion consisting of 500 mg in 10 mL was performed under anesthesia.
Two additional ICV AON injections of 250 mg in 5 mL each were per-
formed 2 and 3 weeks after surgery in freely moving mice, resulting in
a total dose of 1 mg AON per mouse. Bodyweight was recorded every
week post surgery. Mice were sacrificed 3.5 months after surgery. The
left hemisphere was dissected and snap frozen in liquid nitrogen, the
right hemisphere was placed in 4% paraformaldehyde and fixed over-
night at 4C. The fixed tissue was placed in 30% sucrose the next day
and snap frozen in isopentane on dry ice.
RNA Isolation and RT-PCR
Cells were detached by trypsinization (Life Technologies) and subse-
quently spun down. RNA was collected from the cell pellets using the
ReliaPrep RNA Cell Miniprep Kit (Promega) according to manufac-
turer’s instructions. RNA from the mouse brain tissue was obtained
from fresh frozen material by homogenization with a bullet blender
BBX24 (Next Advance) for 3 min on setting 8, using pink beads
(Next Advance), 500 mL TRIzol (Ambion and Thermo Fisher Scien-
tific), and approximately 30 mg of tissue. After 5 min of incubation,
100 mL of chloroform was added and samples were spun down at
10,000 g for 15 min. The aqueous phase was removed and added to
an equal volume of 70% ethanol. Further RNA purification was per-
formed using the PureLink RNA Mini Kit (Thermo Fisher Scientific)
in accordance with the manufacturer’s protocol and using a 15 min
DNase step. RNA was eluted in 80 mL nuclease free water.For cDNA synthesis, 500 ng of RNA was used as input for the Tran-
scriptor First Strand cDNA Synthesis Kit (Roche). The cDNA synthe-
sis reaction was performed using oligoDT primers, or a gene-specific
primer in the 30 UTR region of humanATXN3 for 45min at 50C and
stopped for 5 min at 85C, according to manufacturer’s instructions.
PCR was subsequently performed using primers in ATXN3 exon 4
and 11 (see Table 2) with 1 mL cDNA as input. The PCR reaction con-
tained 0.25 mM dNTPs, 1 U Faststart Taq DNA Polymerase (Roche),
and 10 pmol forward and reverse primers (Eurogentec). PCR cycling
was started with 4 min initial denaturation at 95C, followed by a total
of 36 cycles with 30 s of denaturation at 95C, 30 s of annealing at
59C, and 1 min extension at 72C. At the end of the program, a final
elongation step of 7 min at 72C was used. PCR products were sepa-
rated by electrophoresis on a 1.5% agarose gel containing 0.002%
ethidium bromide. Bands of skipped products were excised from
the gel, purified using a DNA extraction kit (Macherey-Nagel)
according to manufacturer’s instructions, and the sequence was ob-
tained by Sanger sequencing (Macrogen).
Protein Isolation and Western Blotting
Protein from transfected cells was isolated by trypsinization and
centrifugation of cells, after which, the pellet was dissolved in radio-
immunoprecipitation assay (RIPA) buffer. Protein from 30 mg
mouse brain tissue was isolated by homogenization with a bullet
blender BBX24 for 3 min at intensity 8, in 500 mL RIPA buffer with
0.5 mm glass beads. Next, protein lysates were incubated in a head-
over-head rotor at 4C for 30 min. Protein concentration was deter-
mined using the bicinchoninic acid kit (Thermo Fisher Scientific),
with BSA as a standard. Protein samples were separated using 10%
SDS-PAGE with Laemmli sample buffer after boiling for 5 min at
100C. Proteins were blotted onto a nitrocellulose membrane using
the Trans Blot Turbo system (Bio-Rad) for 10 min at 1.3 A. Blocking
of membranes was done with 5% low-fat milk powder in Tris-buff-
ered saline (TBS) for 1 hr at room temperature. Membranes were
stained using mouse anti-ataxin-3 1H9 (Abcam) at 1:5,000 dilution
and rabbit antitubulin (Proteintech) 1:1,000 overnight at 4C.
Blots were washed and incubated for 1 hr with Odyssey secondaryMolecular Therapy: Nucleic Acids Vol. 8 September 2017 239
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800CW (LI-COR Biosciences) at a 1:5,000 dilution. Membranes
were scanned using the Odyssey infrared imaging system (LI-COR
Biosciences). Protein bands were quantified with the Odyssey soft-
ware version 3.0 using the integrated intensity method. Percentage
of protein modification was calculated based on band intensities as
follows: modified ataxin-3 / (modified ataxin-3 + human ataxin-3
84Q)  100.
Cryosectioning and Immunohistochemistry
Sectioning of paraformaldehyde-fixed mouse brains from four con-
trol AON- and three 10.4 AON-treated mice was performed using
a Leica CM3050 cryostat. Sagittal sections of 25 mm thickness from
the right hemisphere were immediately transferred as free-floating
sections to PBS containing 0.02% sodium azide at room temperature.
Sections were stored at 4C until staining. Prior to staining, sections
were washed three times in PBS with 0.2% Triton X-100 for 10 min
and incubated with mouse on mouse (M.O.M.) mouse IgG blocking
reagent (Vector Laboratories) for 1 hr. Sections were washed and
incubated overnight at 4C with primary antibodies diluted in
M.O.M. protein concentrate diluent (Vector Laboratories). Primary
antibodies used were: mouse anti-ataxin-3 1H9 1:1,000 (Abcam)
and rabbit anti-tyrosine hydroxylase 1:500 (Santa Cruz Biotech-
nology). For assessment of AON distribution, a rabbit antibody bind-
ing the phosphorothioate backbone of AONs was used at 1:10,000
diluted in 1% normal goat serum. After washing, sections were incu-
bated with secondary antibodies, goat anti-mouse Alexa Fluor 594, or
goat anti-rabbit Alexa Fluor 488 (Life Technologies) at 1:500 dilution.
Sections were mounted on superfrost plus coated microscope slides
(Fisher Emergo), coverslipped using EverBrite Hardset Mounting
Medium containing DAPI (Biotium), and cured overnight prior to
fluorescent microscopic examination using a Leica DM-5500 using
63 magnification for assessment of ubiquitin binding or Keyence
BIOREVO BZ-9000 fluorescent microscope for all other analyses at
10 magnification.
Image Analysis of Ataxin-3 Nuclear Intensity
Fluorescent images of substantia nigra were analyzed using ImageJ
(version 1.48).59 Images were converted to 8 bit and the substantia
nigra was automatically selected using a region of interest based on
positive tyrosine hydroxylase green fluorescence (threshold 25–
254). Within this region, ataxin-3 nuclear staining was determined
using the “Analyze Particles” function (circularity 0.15–1.00) based
on red fluorescent staining (threshold 35–254). Background fluores-
cence (intensity 35) was subtracted, and the average fluorescence
intensity per cell was subsequently used to represent intensity of
nuclear ataxin-3. Identical analysis values were used to analyze all
images. Between 400 and 1,300 individual cells were assessed for
10.4- and control AON-treated mice.
Dot-Blot Filter Retardation Assay
To detect aggregated ataxin-3 protein, mouse brain lysates in RIPA
buffer were diluted in PBS to a final concentration of 0.15 mg/mL
with 0.025% SDS. A total volume of 200 mL lysate was then passed240 Molecular Therapy: Nucleic Acids Vol. 8 September 2017through a cellulose acetate membrane of 0.2 mm (Whatman)
mounted in a 96-well vacuum manifold. Three additional washes
were performed using PBS to remove unbound protein. The mem-
brane was blocked using 5% non-fat milk and subsequently stained
for 3 hr with mouse anti-ataxin-3 1H9 1:5,000 (Abcam) and 1 hr
with goat anti-mouse IRDye 800CW 1:10,000 (LI-COR Biosciences).
Dots were quantified with the Odyssey software version 3.0 using the
integrated intensity method.
Plasmids and Mutations
Plasmids for transfection were obtained as previously described.22 In
short, PCR products for cloning were generated with primers flanking
the full-length ATXN3 transcript (see Table 2) using AON transfected
fibroblast cDNA as template. Full-length or exon 10-skipped products
were gel extracted, purified, and ligated in the pGEM-T Easy Vector
(Promega) using the 50-A overhangs. Mutations of the UIMs and
deletion of cysteine 14 was generated using the QuikChange II Site-
Directed Mutagenesis Kit (Agilent Technologies) as described previ-
ously using primers containing the mutation (Table 2).40 Expanded
ataxin-3 with 71Q was obtained by gene synthesis (GenScript), a
mixture of CAG and CAA codons was generated to improve stability
during the cloning process. Constructs were then subcloned into the
pAcGFP-C1 vector (Clontech) using notI digestion, resulting in an
N-terminally GFP-tagged ataxin-3 protein expression. The mCherry-
LacR-RNF8 construct has been described previously.21 Purified
ataxin-3 proteins were produced using the pET28a vector (Merck
Millipore) and BL21 E. coli (New England Biolabs) as previously
described.22 All constructs were verified using Sanger sequencing.
Assessment of Ubiquitin Binding through RNF8 Chromatin
Tethering
Ubiquitin binding assays were performed as previously described.22
Briefly, human U2OS 2-6-3 cells with LacO repeats integrated in
the genome20 were grown on glass coverslips. Cells were transfected
with both mCherry-LacR-RNF821 and GFP-ataxin-3 constructs.
The cells were fixed in 4% paraformaldehyde the following day, and
glass slides were mounted on microscope slides with EverBrite
mounting medium containing DAPI (Biotium). Images were ob-
tained for a minimum of 50 cells (two replicate transfections) positive
for both RNF8 and ataxin-3 fluorescent signals. Due to the LacR
fusion, the RNF8 protein construct localizes to the LacO repeat,
resulting in local chromatin ubiquitination. Subsequently, ataxin-3
proteins localize to the ubiquitinated chromatin through their
UIMs, resulting in colocalization with the mCherry-RNF8. The
GFP intensity, thus representing ubiquitin binding, was quantified.
By drawing a line region of interest across the mCherry-LacR-
RNF8-marked array, the increase in GFP-ataxin-3 at the array was
determined using the LAS AF Lite software (Leica Microsystems).
The signal was background corrected by subtracting background
GFP signal from the peak GFP intensity at the array.
Deubiquitination Assay
The in vitro deubiquitination assay was performed as previously
described.34
www.moleculartherapy.org1.2 mg HIS-ataxin-3 proteins were incubated with 0.5 mg K63-linked
hexa-ubiquitin chains (Boston Biochem) in buffer containing 50 mM
HEPES pH 8, 0.5 mM EDTA, and 1 mM DTT. Incubations were per-
formed for 16 hr at 37C. Reactions were stopped with 4 Laemmli
sample buffer containing b-mercaptoethanol and by boiling the
sample at 100C for 5 min. Samples were run on SDS-PAGE using
10% TGX gels (Bio-Rad). After western blotting, membranes were
probed with anti-ataxin-3 1H9 (1:5,000) and anti-ubiquitin 1:1,000
(UG9511) (Enzo Life Sciences).
Statistical Analyses
The percentage of ataxin-3 protein modification, filter trap assay dot
intensity, and ataxin-3 ubiquitin binding assays were analyzed with
one-way ANOVA using Tukey’s post hoc multiple comparisons
test. Raw intensity values obtained from Oyssey application software
“integrated intensity quantification”method were used for analyses of
filter trap assays and western blots. Western blot protein modification
is reported as percentage modified ataxin-3 of the sum of all human
ataxin-3 bands. Intensity of nuclear ataxin-3 accumulation in sub-
stantia nigra was compared using unpaired Student’s t test. Statistical
analyses were performed using GraphPad Prism software version
6.02. p values < 0.05 were considered statistically significant.
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